Post-earnings recap
Reported
Wed, Oct 24, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a small decline in the stock price. Investors may be cautious due to the lack of revenue data and forward guidance. The management's focus on the product pipeline suggests they are looking to future growth despite current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.41 | N/A | -0.97% |
Overall, management remains focused on long-term growth despite the slight EPS miss. They emphasized the strength of their product portfolio.
Management expressed confidence in ongoing product pipeline.
They highlighted the importance of upcoming clinical trial results.